Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bosutinib + Ruxolitinib|
Bosulif (bosutinib) inhibits SRC and ABL kinases, and has additional activity against other kinases including AXL, TNK2, BTK, resulting in decreased pathway activation and inhibition of tumor cell proliferation (PMID: 12543790, PMID: 19039322, PMID: 26555154). Bosulif (bosutinib) is FDA approved for use in patients with Ph+ (BCR-ABL) chronic myelogenous leukemia (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bosutinib||Bosulif||SKI-606|PF-5208763||ABL Inhibitor (pan) 9 AXL Inhibitor 29 BCR-ABL Inhibitor 29 BTK inhibitor 35 SRC Inhibitor 31 TNK2 Inhibitor 6||Bosulif (bosutinib) inhibits SRC and ABL kinases and has additional activity against other kinases including AXL, TNK2, and BTK, resulting in decreased pathway activation and inhibition of tumor cell proliferation (PMID: 12543790, PMID: 19039322, PMID: 26555154). Bosulif (bosutinib) is FDA-approved for use in adult and pediatric patients 1 year of age and older with Ph+ (BCR-ABL) chronic myelogenous leukemia (FDA.gov).|
|Ruxolitinib||Jakafi||INCB 18424|INCB018424|INCB18424||JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15||Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03654768||Phase II||Bosutinib Dasatinib Nilotinib Dasatinib + Ruxolitinib Bosutinib + Ruxolitinib Nilotinib + Ruxolitinib||Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia||Active, not recruiting||USA||0|
|NCT03610971||Phase II||Nilotinib + Ruxolitinib Imatinib + Ruxolitinib Bosutinib + Ruxolitinib Dasatinib + Ruxolitinib||Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors||Recruiting||USA||0|